How CJC-1295 and Ipamorelin Work: GH Secretagogue Basics

What a growth hormone secretagogue is

A growth hormone secretagogue (GHS) is a compound that stimulates the pituitary gland to release growth hormone (GH). Rather than introducing exogenous GH directly (as with HGH injections), secretagogues trigger the body's own GH pulse — preserving the natural pulsatile release pattern that exogenous GH suppresses.

CJC-1295 and Ipamorelin are the most widely used GHS combination in research and compounding contexts. They work through different receptors and produce a synergistic effect when co-administered.

How CJC-1295 works

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic signal that tells the pituitary to release GH. Natural GHRH has a half-life of a few minutes; CJC-1295 (no DAC) extends this to approximately 30 minutes. CJC-1295 with DAC (Drug Affinity Complex) extends it further to 6–8 days through albumin binding.

CJC-1295 binds the GHRH receptor on pituitary somatotrophs (GH-producing cells) and amplifies the GH pulse that would naturally occur. It does not create a GH pulse on its own — it amplifies the one that's coming.

How Ipamorelin works

Ipamorelin is a ghrelin mimetic — it binds the GH secretagogue receptor (GHS-R), which is the receptor for ghrelin (the "hunger hormone"). Ghrelin receptor activation triggers GH release independently of the GHRH pathway.

Ipamorelin is considered one of the most selective GH secretagogues studied — it stimulates GH release without meaningfully elevating cortisol or prolactin, which some older secretagogues (GHRP-2, GHRP-6) do. This selectivity is why it became the preferred GHRP for clinical research protocols.

Why they're stacked: dual pathway synergy

CJC-1295 (GHRH receptor) and Ipamorelin (GHS-R/ghrelin receptor) activate GH release through two separate receptor systems. Co-administration produces a GH pulse larger than either compound alone — the effect is more than additive (synergistic), because the two pathways interact at the pituitary level to amplify the secretory signal.

This is the scientific basis for the standard combination protocol: CJC-1295 + Ipamorelin together rather than either alone.

CJC-1295 without DAC vs. with DAC: the practical difference

The no-DAC form preserves pulsatility, which many practitioners consider advantageous for maintaining natural GH axis feedback. The DAC form is used when the goal is sustained IGF-1 elevation over days from less frequent dosing. Your prescription will specify which form; if it just says "CJC-1295," confirm with your pharmacy.

The fasted-state timing requirement

Both compounds are most effective when injected in a fasted state — typically first thing in the morning before eating, or at bedtime at least 2 hours after the last meal. The reason: insulin suppresses GH secretion at the pituitary level. Injecting when insulin is at its lowest (during fasting) maximizes the amplitude of the GH pulse these compounds trigger.

A meal 30 minutes before injection can significantly blunt the GH response. This timing constraint is specific to GH secretagogues and does not apply to most other peptides (BPC-157, TB-500, GLP-1s) in the same way.

Reconstitution and dosing recap

See the full CJC-1295/Ipamorelin reconstitution guide for vial math. Common setup: 5 mg + 5 mg blended vial + 2 mL bac water = 8 units for a 200 mcg + 200 mcg dose. Use the calculator for your specific setup.

What secretagogues are not

GH secretagogues are not exogenous growth hormone. They do not inject GH directly. They stimulate the pituitary to produce and release more of the body's own GH, within the limits of what the pituitary can generate. This distinction matters for regulatory status, mechanism, and expected effect size.

For the same reason, GH secretagogues are not a substitute for prescribed HGH in conditions of true GH deficiency where the pituitary cannot produce adequate GH. In those cases, the pituitary cannot respond to a secretagogue signal adequately. Confirm with your prescribing provider.